Synapse - Works

Results (39034)

Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience

Meeting Abstract

Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer

Meeting Abstract

Cadoo, K.; Kaufman, P. A.; Hudis, C.; Chang, C.; Berrak, E.; Song, J.; Seidman, A. D.; Traina, T. A.
Cancer Research (2016)

Fulltext@MSK | Save

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

Meeting Abstract

Sikov, W. M.; Berry, D. A.; Perou, C. M.; Singh, B.; Cirrincione, C. T.; Tolaney, S. M.; Somlo, G.; Port, E. R.; Qamar, R.; Sturtz, K.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience

Meeting Abstract

Mukku, R. B.; Verma, S.; Liu, J.; Steingart, R.; Hudis, C.; Yu, A. F.; Dang, C.
Cancer Research (2016)

Fulltext@MSK | Save

Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling

Meeting Abstract

Morikawa, A.; De Stanchina, E.; Patil, S.; Chandarlapaty, S.; Li, B. T.; Norton, L.; Seidman, A. D.
Cancer Research (2016)

Fulltext@MSK | Save

Feasibility of a non-hormonal vaginal moisturizer in postmenopausal cancer survivors

Meeting Abstract

Carter, J.; Seidel, B.; Stabile, C.; Dickler, M.; Goldfrank, D.; Baser, R.; Goldfarb, S.
Cancer Research (2016)

Fulltext@MSK | Save

A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

Meeting Abstract

Gucalp, A.; Hudis, C.; Norton, L.; Patil, S.; Kurman, M. R.; Eisner, J. R.; Moore, W. R.; Traina, T. A.
Cancer Research (2016)

Fulltext@MSK | Save

Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer

Meeting Abstract

Forero, A.; Burris, H. 3rd; Mita, M.; Specht, J.; Weise, A.; Liu, M. C.; Modi, S.; Pusztai, L.; Kostic, A.; Yang, J.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: Prognosis or prediction?

Meeting Abstract

Miller, K.; Krop, I.; Schwartzberg, L.; Abramson, V.; Garcia-Estevez, L.; Eakle, J.; Nanda, R.; Yardley, D.; Ademuyiwa, F.; Chan, S.; more...
Cancer Research (2016)

Fulltext@MSK | Save

A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)

Meeting Abstract

Jhaveri, K.; Teplinsky, E.; Chandarlapaty, S.; Solit, D.; Cadoo, K.; Speyer, J.; D'Andrea, G.; Adams, S.; Patil, S.; Haque, S.; more...
Cancer Research (2016)

Fulltext@MSK | Save